Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3400 - Immune Related Adverse Events Associated with Ipilimumab and Nivolumab


10 Sep 2017


Poster display session


Supportive Care and Symptom Management;  Immunotherapy


Bernardo Rapoport


Annals of Oncology (2017) 28 (suppl_5): v543-v567. 10.1093/annonc/mdx388


B. Rapoport, R.I. Van Eeden, T. Smit

Author affiliations

  • Medical Oncology, The Medical Oncology Centre of Rosebank, 2196 - Johannesburg/ZA


Abstract 3400


Immune related adverse events (IrAEs) are unique and completely different from what we have seen previously. There is no prospective data on these toxicities and guidelines are based on symptomatic management from the ongoing clinical trials. Ipilimumab and nivolumab induce irAEs to the skin, gastrointestinal, liver, endocrine and other systems.


A retrospective review of data from 45 patient records were used to describe the IrAE’s associated with 19 patients treated with Ipilimumab and 25 patients treated with Nivolumab and 1 patient with combination of ipilimumab and nivolumab. This is a single centre review in an expanded access programme/clinical trial setting.


A total of 45 patients (28 males, 17 females) were analyzed. The median age was 63 years. Three patients with metastatic melanoma, 18 with non-small cell lung cancer (NSCLC), 2 with renal cell carcinoma and 2 with Hodgkin’s disease were treated with nivolumab and 19 with metastatic melanoma received ipilimumab. One patient with combination of ipilimumab and nivolumab. In total 167 cycles of nivolumab (median = 4, range 1-16) and 60 cycles of ipilimumab (median = 4 cycles, range 1-4) were administered. The patient receiving combination of ipilimumab and nivolumab received 1 cycle. Seven IrAEs are described in 15 ipilimumab treated patients. These include endocrinopathy in 3 patients (hypophysitis in patient and hyphothyroidsm in 2 patients), colitis in 3 patients (1 required infliximab) and hepatitis in 1 patient. Among the patients treated with nivolumab, 7 IrAEs were documented. These included pneumonitis in 2 patients, skin rash in 3 patients, mild diarrhea in 1 patient and mild uveitis in 1 patient. One patient developed autoimmune thrombocytopenia, and nephritis. Three chest infections were documented including pulmonary tuberculosis in a NSCLC patient. The patient receiving combination ipilimumab and nivolumab had grade 4 skin toxicity requiring treatment discontinuation. No IrAE related deaths were document.


A plethora of irAEs are described with anti-PD1 and anti-CTLA4 antibodies. Colitis was more common with ipilimumab while pneumonitis more common with nivolumab. Prompt IrAE’s diagnosis will result in decreased morbidity and mortality.

Clinical trial identification


Legal entity responsible for the study

BL Rapoport




B. Rapoport: MSD, BMS and Roche Speaker Engagements, Advisory Board and Contract Research All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.